12/3
04:01 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12/1
07:13 am
sndx
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
Medium
Report
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
12/1
07:00 am
sndx
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
Medium
Report
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
11/29
10:12 pm
sndx
Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth [Seeking Alpha]
Medium
Report
Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth [Seeking Alpha]
11/28
12:09 pm
sndx
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating [Yahoo! Finance]
Low
Report
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating [Yahoo! Finance]
11/26
02:19 pm
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
09:44 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at Barclays PLC from $22.00 to $35.00. They now have an "overweight" rating on the stock.
Medium
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at Barclays PLC from $22.00 to $35.00. They now have an "overweight" rating on the stock.
11/17
07:26 pm
sndx
Syndax Pharmaceuticals (SNDX): Assessing Value After Revuforj FDA Expansion and Revenue Surge [Yahoo! Finance]
Low
Report
Syndax Pharmaceuticals (SNDX): Assessing Value After Revuforj FDA Expansion and Revenue Surge [Yahoo! Finance]
11/16
10:26 pm
sndx
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating [Yahoo! Finance]
Low
Report
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating [Yahoo! Finance]
11/12
12:22 pm
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target lowered by analysts at JPMorgan Chase & Co. from $40.00 to $33.00. They now have an "overweight" rating on the stock.
Low
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target lowered by analysts at JPMorgan Chase & Co. from $40.00 to $33.00. They now have an "overweight" rating on the stock.
11/10
02:04 pm
sndx
Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Low
Report
Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/6
05:50 am
sndx
Analyst Estimates: Here's What Brokers Think Of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Third-Quarter Report [Yahoo! Finance]
Low
Report
Analyst Estimates: Here's What Brokers Think Of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Third-Quarter Report [Yahoo! Finance]
11/5
04:01 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/4
11:05 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at UBS Group AG from $35.00 to $38.00. They now have a "buy" rating on the stock.
Low
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at UBS Group AG from $35.00 to $38.00. They now have a "buy" rating on the stock.
11/4
09:06 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at Barclays PLC from $19.00 to $22.00. They now have an "overweight" rating on the stock.
High
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at Barclays PLC from $19.00 to $22.00. They now have an "overweight" rating on the stock.
11/3
04:01 pm
sndx
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
High
Report
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
11/3
09:08 am
sndx
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
Low
Report
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
11/3
09:08 am
sndx
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
Low
Report
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
10/30
07:00 am
sndx
Syndax Announces Participation in November Investor Conferences
Low
Report
Syndax Announces Participation in November Investor Conferences
10/27
08:06 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $56.00 price target on the stock.
Medium
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $56.00 price target on the stock.
10/27
08:06 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Medium
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
10/27
07:00 am
sndx
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
Low
Report
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
10/25
05:39 pm
sndx
Syndax Pharmaceuticals (SNDX): Valuation in Focus After FDA Approval of Revuforj for NPM1-Mutated AML [Yahoo! Finance]
Low
Report
Syndax Pharmaceuticals (SNDX): Valuation in Focus After FDA Approval of Revuforj for NPM1-Mutated AML [Yahoo! Finance]
10/25
12:12 pm
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/24
08:49 pm
sndx
Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript [Seeking Alpha]
Low
Report
Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript [Seeking Alpha]